Please assess the completion status of the following clinical trial:

Trial Title: Individualized Therapy For Asthma in Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 12-59 months of age.~* If the child is not currently taking long-term asthma controller therapy (meaning that the child has taken no inhaled corticosteroid or leukotriene receptor antagonist medication whatsoever over the past 6 months), then one of the following criteria must be met:~  * Daytime asthma symptoms more than two days per week (average over the past 4 weeks),~ * At least one nighttime awakening from asthma (over the past 4 weeks),~ * Two or more asthma exacerbations requiring systemic corticosteroids in the previous 6 months,~ * Four or more wheezing episodes in the previous 12 months.~* If the child is currently taking long-term asthma controller therapy (meaning that the child has taken daily or intermittent/as-needed inhaled corticosteroid or leukotriene receptor antagonist over the past 6 months), then one of the following criteria must be met:~  * Taking inhaled corticosteroid or leukotriene receptor antagonist for more than 3 months (or more than 90 days) out of the previous 6 months (or 180 days),~ * Daytime asthma symptoms more than two days per week (average over the past 4 weeks),~ * More than one nighttime awakening from asthma (over the past 4 weeks),~ * Two or more asthma exacerbations requiring systemic corticosteroids in the previous 12 months,~ * Four or more wheezing episodes in the previous 12 months.~* Up to date with immunizations, including varicella (unless the subject has already had clinical varicella).~* Willingness to provide informed consent by the child's parent or guardian.~Exclusion Criteria:~* Allergic reaction to the study medications or any component of the study drugs, including (but not limited to) urticaria, rash, angioedema, or hypotension following delivery,~* Chronic medical disorders that could interfere with drug metabolism/excretion (for instance chronic hepatic, biliary, or renal disease),~* Chronic medical disorders that may increase the risk of drug-related injury, including (but not limited to):~  * Osteogenesis imperfecta (increased risk of bone demineralization/fracture with corticosteroid therapy),~ * Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy),~ * G6PD deficiency (increased risk of hemolytic anemia with acetaminophen use),~ * Phenylketonuria (potential for aspartame exposure with study interventions),~ * Seizure disorder treated with anticonvulsants (risk of acetaminophen toxicity with carbamazepine), or~ * History of clotting disorders or Factor deficiency (increased risk of bleeding with corticosteroids),~* Co-morbid disorders associated with wheezing including (but not limited to) immune deficiency disorders, cystic fibrosis, aspiration, clinically-relevant gastroesophageal reflux, tracheomalacia, congenital airway anomalies (clefts, fistulas, slings, rings), bronchiectasis, bronchopulmonary dysplasia, and/or history of premature birth before 35 weeks gestation,~* Significant developmental delay/failure to thrive, defined as 5th percentile for height and/or weight or crossing of two major percentile lines during the last year for age and sex,~* History of a near-fatal asthma exacerbation requiring intubation or assisted ventilation,~* No primary medical caregiver (e.g., a nurse practitioner, physician assistant, physician, or group medical practice such as a hospital-based clinic) whom the subject can contact for primary medical care,~* Three or more hospitalizations in the previous 12 months for wheezing or respiratory illnesses,~* Treatment with 5 or more courses of systemic corticosteroids (oral, intramuscular or intravenous) in the past 6 months,~* Current use of higher than step 2 NAEPP asthma guideline therapy~* If receiving allergy shots, change in the dose within the past 3 months.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Crossover sequence 1 (Type: EXPERIMENTAL): daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
- Crossover sequence 2 (Type: EXPERIMENTAL): daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
- Crossover sequence 3 (Type: EXPERIMENTAL): daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
- Crossover sequence 4 (Type: EXPERIMENTAL): daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
- Crossover sequence 5 (Type: EXPERIMENTAL): as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
- Crossover sequence 6 (Type: EXPERIMENTAL): as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate

Based on this trial design, predict the completion outcome and termination type (if applicable).